ClinicalTrials.gg
CompletedNCT03808844Updated Sep 13, 2019

A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion for the Induction of General Anesthesia in Elective Surgery Subjects

A Phase 3 interventional study of HSK3486 and Propofol in Induction of Anesthesia, sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2019-09-13.

Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This is a multi-center, randomized, double-blind, propofol-controlled phase III clinical trial. The primary objective is to compare the efficacy and safety between propofol and HSK3486 for the induction of general anesthesia in elective surgery subjects, so as to provide reference for marketing registration of HSK3486.

02

Conditions studied

  • Induction of Anesthesia
03

In context

Lead sponsor

Sichuan Haisco Pharmaceutical Group Co., Ltd is the lead sponsor of 30 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In-patients requiring tracheal intubation under general anesthesia for non-emergency, non-cardiothoracic, and non-extracerebral elective surgeries;
  2. Male or female, ages between 18-64 (inclusive);
  3. ASA () Class I-II (see Appendix 4);
  4. (BMI) ≥18 and ≤30 kg/m2;
  5. Vital signs: Respiratory rate ≥10 and ≤24 breaths per minute; blood oxygen saturation (SpO2) when inhaling ≥95%; systolic blood pressure (SBP) ≥90 mmHg and ≤160 mmHg; diastolic blood pressure (DBP) ≥60 mmHg and ≤100 mmHg; heart rate ≥55 and ≤100 bpm;
  6. Subjects must understand the procedures and methods of this study, and be willing to provide and to complete the trial in strict accordance with study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patients with to general anesthesia or previous history of anesthesia accidents;
  2. Known to and ingredients found in propofol and HSK3486 injections (soybean oil, glycerin, triglycerides, egg lecithin, sodium oleate, and sodium hydroxide), benzodiazepines, opioids, rocuronium bromide, sevoflurane, atropine, and neostigmine; cross-reactivity to halogenated anesthetics, jaundice or unexplained fever from previous use of halogenated anesthetics; contraindications to propofol;
  3. Medical history or evidence of any of the following prior to screening/at baseline, which may increase sedation/anesthesia risk:

    1. History of cardiovascular diseases: Uncontrolled hypertension or SBP >160 mmHg and/or DBP >100 mmHg despite antihypertensive treatment, severe arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within 6 months before screening, history of tachycardia/bradycardia requiring medication, third-degree atrioventricular block or interval ≥450 ms (Fridericia's correction formula, see Appendix 2) during screening;
    2. Respiratory system disorders: Respiratory insufficiency, history of obstructive pulmonary disease, history of bronchospasm requiring treatment within 3 months prior to screening, acute respiratory tract infection with obvious symptoms such as fever, wheezing, or productive cough within 1 week prior to baseline;
    3. History of cerebrovascular disease: History of craniocerebral injury, convulsions, epilepsy, intracranial hypertension, cerebral aneurysm, or cerebrovascular accident; history of schizophrenia, mania, chronic use of antipsychotics, or cognitive impairment;
    4. Gastrointestinal disease history: Gastrointestinal retention, active hemorrhage, or circumstances that may lead to reflux and aspiration;
    5. Patient with a history of uncontrolled and liver, kidney, blood system, nervous system or metabolic system diseases judged by the investigator to be unsuitable for this trial;
    6. History of alcohol abuse within 3 months prior to screening, abuse defined as average of >2 units of alcohol per day (1 unit = 360 mL beer or 45 mL liquor with 40% alcohol or 150 mL wine);
    7. History of drug abuse within 3 months prior to screening;
    8. Serious infection, trauma, or major surgery within 4 weeks prior to screening;
  4. Any one of the following respiratory risks before/during screening:

    1. Asthma history, and stridor;
    2. Sleep apnea syndrome;
    3. History of malignant hyperthermia or family history;
    4. History of failed tracheal intubation;
    5. Judged by the investigator to have difficult airway or judged as difficult tracheal intubation (modified Mallampati score III or IV );
  5. In receipt of any of the following drugs or therapies prior to screening:

    1. Participated in other drug trials within 1 month prior to screening;
    2. In receipt of medications that may affect QT interval within 2 weeks prior to screening (see Appendix 5);
    3. In receipt of medications that induce or inhibit cytochrome P450 isoenzyme CYP2B6 within 2 weeks prior to screening (see Appendix 6);
    4. In receipt of propofol, other sedatives/anesthetics, and/or opioid analgesics or compounds containing analgesics within 3 days prior to screening.
  6. Laboratory results meeting any of the following criteria during screening/at baseline, confirmed by re-examination:

    1. ≤1.5×109/L;
    2. count \<80×109/L;
    3. \<90 g/L (no blood transfusion within the last 14 days);
    4. and/or AST ≥2.0× (ULN);
    5. Total ≥2.0×ULN;
    6. Serum creatinine ≥1.5×ULN.
  7. Women who are pregnant or breastfeeding; women of or men who are unwilling to use during the trial; subjects who are planning pregnancy within 1 month after the completion of the trial (including male subjects);
  8. Subjects judged by the investigator to be unsuitable for participating in this trial for any reason.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    HSK3486

    0.4mg/kg/0.2 mg/kg

    Drug: HSK3486

  • Active comparator
    Propofol

    2.0mg/kg/1.0mg/kg

    Drug: Propofol

Interventions

  • Initial dose of 0.4 mg/kg followed by 0.2 mg/kg if needed.

  • Initial dose of 2.0 mg/kg followed by 1.0 mg/kg if needed

06

What researchers measure

Primary outcomes

  1. The success rate of induction of anesthesia

    Time frame: During induction of general anesthesia on day 1

Secondary outcomes

  1. Time to successful anesthetic induction

    Time frame: From the initial administration of the investigational drug to the first time when MOAA/S is ≤1 on day 1

  2. Time to loss of eyelash reflex

    Time frame: From the initial administration of the investigational drug to loss of eyelash reflex on day 1

  3. Use of the investigational drug and alternative drugs

    Time frame: During induction of general anesthesia on day 1

  4. Use of the alternative drugs

    Time frame: During induction of general anesthesia on day 1

  5. Changes in bispectral index (BIS)(score:0~100)

    Time frame: During induction of general anesthesia on day 1

  6. Number of patients with adverse events

    Safety endpoints

    Time frame: Pre-dose to 48 hours post-dose

07

Study locations

1 site
  • West China Hospital of Sichuan University
    Chengdu, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Aug 2019, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2019
First posted
Jan 18, 2019
StartActual
Mar 22, 2019
Primary completionActual
Aug 14, 2019
CompletionActual
Sep 3, 2019
Last update
Sep 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03808844
Responsible party
Sponsor
First posted
Jan 18, 2019
Start date
Mar 22, 2019
Primary completion
Aug 14, 2019
Completion
Sep 3, 2019
Last update
Sep 13, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion